{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T04:02:41Z","timestamp":1747454561659,"version":"3.40.5"},"reference-count":30,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Cancer-associated thrombosis (CAT) remains a challenging aspect of managing patients with cancer. This review discusses evidence regarding anticoagulants in the treatment of CAT, with particular emphasis on direct oral anticoagulants (DOAC). Apixaban, rivaroxaban and edoxaban have proven attractive alternatives to low-molecular weight heparins, and interactions with medical cancer treatment does not pose a major challenge. The majority of guidelines have endorsed the use of DOAC, and we highlight points to consider when choosing the optimal anticoagulant for the individual patient.<\/jats:p>","DOI":"10.61409\/v04240299","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T13:46:53Z","timestamp":1730900813000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Direct oral anticoagulants for the treatment of cancer-associated thrombosis"],"prefix":"10.61409","author":[{"given":"Maja Hellfritzsch","family":"Poulsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"K\u00fcmler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten Kj\u00f8bek","family":"Lamberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina Halgaard","family":"Ruhlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Jensvoll H, Severinsen MT, Hammerstr\u00f8m J et al. Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clin Epidemiol. 2015;7:401-410. https:\/\/doi.org\/10.2147\/CLEP.S84279","DOI":"10.2147\/CLEP.S84279"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Carrier M, Lazo-Langner A, Shivakumar S et al. Screening for occult cancer in unprovoked venous thromboembolism. N Engl J Med. 2015;373(8):697-704. https:\/\/doi.org\/10.1056\/NEJMoa1506623","DOI":"10.1056\/NEJMoa1506623"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Lee AYY, Kamphuisen PW, Meyer G et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(7):677-686. https:\/\/doi.org\/10.1001\/jama.2015.9243","DOI":"10.1001\/jama.2015.9243"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Lee AYY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153. https:\/\/doi.org\/10.1056\/NEJMoa025313","DOI":"10.1056\/NEJMoa025313"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Agnelli G, Becattini C, Meyer G et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599-1607. https:\/\/doi.org\/10.1056\/NEJMoa1915103","DOI":"10.1056\/NEJMoa1915103"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Young AM, Marshall A, Thirlwall J et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017-2023. https:\/\/doi.org\/10.1200\/JCO.2018.78.8034","DOI":"10.1200\/JCO.2018.78.8034"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Raskob GE, van Es N, Verhamme P et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615-624. https:\/\/doi.org\/10.1056\/NEJMoa1711948","DOI":"10.1056\/NEJMoa1711948"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"ref8","unstructured":"Medicinr\u00e5det. Medicinr\u00e5dets behandlingsvejledning vedr\u00f8rende l\u00e6gemidler til behandling af ven\u00f8s tromboembolisme hos patienter med kr\u00e6ft. https:\/\/medicinraadet.dk\/anbefalinger-og-vejledninger\/behandlingsvejledninger-og-laegemiddelrekommandationer\/behandling-af-venose-tromboembolier-hos-kraeftpatienter (1. feb 2024)."},{"key":"ref9","unstructured":"Kragholm K, Hellfritzsch M, Pareek M et al. National behandlingsvejledning: Antikoagulationsbehandling. https:\/\/www.cardio.dk\/ak (1. feb 2024)."},{"key":"ref10","unstructured":"Rasmussen M, Dorff M, Holt MI et al.: Cancer og ven\u00f8s tromboembolisme. Dansk Selskab for Trombose og H\u00e6mostase, 2020. https:\/\/dsth.dk\/03e_rapporter.html (1. feb 2024)."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Lyman GH, Carrier M, Ay C et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974. https:\/\/doi.org\/10.1182\/bloodadvances.2020003442","DOI":"10.1182\/bloodadvances.2020003442"},{"key":"ref12","unstructured":"Danske Regioner. Vederlagsfri udlevering af medicin. https:\/\/www.regioner.dk\/sundhed\/medicin\/vederlagsfri-udlevering-af-medicin\/ (26. apr 2024)."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Russo V, Bottino R, Rago A et al. Atrial fibrillation and malignancy: the clinical performance of non-vitamin K oral anticoagulants-a systematic review. Semin Thromb Hemost. 2019;45(2):205-214. https:\/\/doi.org\/10.1055\/s-0038-1661386","DOI":"10.1055\/s-0038-1661386"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Schrag D, Uno H, Rosovsky R et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA. 2023;329(22):1924-1933. https:\/\/doi.org\/10.1001\/jama.2023.7843","DOI":"10.1001\/jama.2023.7843"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Planquette B, Bertoletti L, Charles-Nelson A et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest. 2022;161(3):781-790. https:\/\/doi.org\/10.1016\/j.chest.2021.09.037","DOI":"10.1016\/j.chest.2021.09.037"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"McBane RD, Wysokinski WE, Le-Rademacher JG et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020;18(2):411-421. https:\/\/doi.org\/10.1111\/jth.14662","DOI":"10.1111\/jth.14662"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Kraaijpoel N, Di Nisio M, Mulder FI et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018;118(8):1439-1449. https:\/\/doi.org\/10.1055\/s-0038-1667001","DOI":"10.1055\/s-0038-1667001"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Agnelli G, Mu\u00f1oz A, Franco L et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thromb Haemost. 2022;122(5):796-807. https:\/\/doi.org\/10.1055\/s-0041-1735194","DOI":"10.1055\/s-0041-1735194"},{"key":"ref19","unstructured":"Egholm G, Olesen J, Lein\u00f8e E et al. Antikoagulationsbehandling til s\u00e6rlige patientpopulationer. Ugeskr L\u00e6ger 2024;186:V05240367."},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Prandoni P, Lensing AWA, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-3488. https:\/\/doi.org\/10.1182\/blood-2002-01-0108","DOI":"10.1182\/blood-2002-01-0108"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Nouhravesh N, Sindet-Pedersen C, Hellfritzsch M et al. Infrequent transition to direct oral anticoagulants in patients with cancer. Dan Med J. 2024;71(2):A05230278. https:\/\/doi.org\/10.61409\/A05230278","DOI":"10.61409\/A05230278"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Hellfritzsch M, Henriksen JN, Holt MI, Grove EL. Drug-drug interactions in the treatment of cancer-associated venous thromboembolism with direct oral anticoagulants. Semin Thromb Hemost. 2024;50(3):489-498. https:\/\/doi.org\/10.1055\/s-0043-1762596","DOI":"10.1055\/s-0043-1762596"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Verso M, Munoz A, Bauersachs R et al. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. Eur J Cancer. 2021;148:371-381. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.026","DOI":"10.1016\/j.ejca.2021.02.026"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Frere C, Farge D, Schrag D et al. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol. 2022;15(1):69. https:\/\/doi.org\/10.1186\/s13045-022-01289-1","DOI":"10.1186\/s13045-022-01289-1"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Carrier M, Le Gal G, Cho R et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009;7(5):760-765. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03326.x","DOI":"10.1111\/j.1538-7836.2009.03326.x"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Schulman S. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood. 2017;129(25):3285-3293. https:\/\/doi.org\/10.1182\/blood-2017-03-742304","DOI":"10.1182\/blood-2017-03-742304"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Schulman S, Zondag M, Linkins L, et al. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. J Thromb Haemost. 2015;13(6):1010-1018. https:\/\/doi.org\/10.1111\/jth.12955","DOI":"10.1111\/jth.12955"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"McBane RD, Loprinzi CL, Zemla T, et al. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. J Thromb Haemost. 2024;22(6):1704-1714. https:\/\/doi.org\/10.1016\/j.jtha.2024.03.011","DOI":"10.1016\/j.jtha.2024.03.011"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020;38(5):496-520. https:\/\/doi.org\/10.1200\/JCO.19.01461","DOI":"10.1200\/JCO.19.01461"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T06:48:17Z","timestamp":1747378097000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V04240299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":30,"URL":"https:\/\/doi.org\/10.61409\/v04240299","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}